帕利哌酮缓释片与利培酮治疗精神分裂症阴性症状的对照研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (7): 819-822.

帕利哌酮缓释片与利培酮治疗精神分裂症阴性症状的对照研究

袁国锋¹, 俞玉礼²

¹杭州市公安局安康医院精神二科三病区,杭州 311113,浙江;
²杭州市余杭区仓前镇社区卫生服务中心药剂科,杭州 311000,浙江

收稿日期:2011-04-21 修回日期:2011-05-12 出版日期:2011-07-26 发布日期:2011-09-22
作者简介:袁国锋,男,副主任医师,研究方向:精神药理学。Tel: 13857153630 E-mail: yuanguofeng123@163.com

Control study of paliperidone extended-release tablet and risperidone on negative symptoms of schizophrenia

YUAN Guo-feng¹, YU Yu-li²

¹Ankang Hospital of Hangzhou Security Bureau, Hangzhou 311113, Zhejiang,China;
²Community Center of Cangqian Yuhang, Hangzhou 311000, Zhejiang,China

Received:2011-04-21 Revised:2011-05-12 Online:2011-07-26 Published:2011-09-22

摘要/Abstract

摘要： 目的: 探讨帕利哌酮缓释片与利培酮对精神分裂症阴性症状的疗效和安全性。方法: 分别使用帕利哌酮缓释片与利培酮对60例以阴性症状为主精神分裂症患者治疗8周,用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)分别在治疗前、治疗第4周和第8周末评定疗效和安全性。结果: 研究组显效率和有效率分别为 63.3%和80%, 对照组分别为60%和 76.7%, 两组比较, 差异无统计学意义(P>0.05)。两组PANSS评分治疗后均较治疗前明显下降(P<0.05), 研究组阴性症状因子分在治疗4周和8周时分别为(15.40±1.04)分和(12.80±0.76)分,显著低于对照组的(20.60±1.13)分和(18.10±0.71)分, 两组比较, 差异有统计学意义(P<0.05);研究组第8周末PANSS总分为(42.90±0.84)分,低于对照组的(44.80±0.61)分,有统计学差异(P<0.05)。研究组的不良反应以锥体外系反应和嗜睡为主,对照组以锥体外系反应和失眠、体重增加和视物模糊为主,两组的不良反应相当,均未见严重不良反应。结论: 帕利哌酮缓释片是一种安全有效的抗精神病药,能够显著改善精神分裂症的阴性症状。

关键词: 精神分裂症, 帕利哌酮缓释片, 利培酮片, 阴性症状

Abstract: AIM: To study the efficacy and safety of paliperidone extended-release tablet(Paliperidone-ER) and Risperidone on negative symptoms of schizophrenia.METHODS: Sixty cases of schizophrenics with prominent negative symptoms were randomly divided into study group(n=30)and control group(n=30).Thirty cases of Paliperidone-ER treated patients were compared with thirty cases of Risperidone treated patients.The duration of study was 8 weeks.The therapeutic efficacy and safety were assessed with the PANSS and TESS, respectively.RESULTS: The significantly effective rate and effective rate of Paliperidone-ER were 63.3% and 80%, and of Risperidone were 60% and 76.7% respectively, and there were no significant differences between two groups(P>0.05).Paliperidone-ER group showed lower negative symptom score at the fourth week(15.40±1.04) and at the eighth week(12.80±0.76) than Risperidone group, although the scores decreased at the fourth week (20.60±1.13) and at the eighth week (18.10±0.71). There were significant differences between two groups(P<0.05).At the eighth week ,the full score of PANSS of study group was (42.90±0.84), the full score of PANSS of control group was(44.80±0.61). There were significant differences between two groups(P<0.05).The TESS of study group were EPS and drowsiness. The TESS of control group were EPS,wakefulness,increase of weight and faintness eyesight. There were no severe adverse effects in two groups.CONCLUSION: Paliperidone-ER is an effective and safe antipsychotic drug with more showing significant improvement compared with Risperidone in negative symptoms.

Key words: Schizophrenia, Paliperidone extended-release tablet, Risperidone, Negative symptom

中图分类号:

R749.3

袁国锋, 俞玉礼. 帕利哌酮缓释片与利培酮治疗精神分裂症阴性症状的对照研究[J]. 中国临床药理学与治疗学, 2011, 16(7): 819-822.

YUAN Guo-feng, YU Yu-li. Control study of paliperidone extended-release tablet and risperidone on negative symptoms of schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 819-822.

参考文献

[1] Canuso CM, Dirks B, Carothers J, et al. Randomized, double blind. p1acebo controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacer bated schizophrenia[J]. Am J Psychiatry, 2009, 166(6) : 691- 701.
[2] 中华医学会精神科分会.中国精神障碍疾病诊断及分类标准(第三版)[M].济南:山东科技出版社,2001:75-77.
[3] 张明圆.精神科评定量表手册[M].长沙:湖南科学技术出版社,1993:81-102.
[4] Fowler JA, Bettinger TL, Argo TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia[J]. Clin Ther, 2008, 30 (2): 231-248.
[5] 唐建良.帕利哌酮缓释片与利培酮治疗精神分裂症和分裂样精神病的对照研究[J].中国临床药理学与治疗学,2010,15(9):1060-1063.
[6] Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trim data[J]. Neuropsychiatr Dis Treat,2007, 3(6) : 869- 897.
[7] Marder SR,Kramer M,Ford L,et al. Efficacy and safety of paliperidone extended -release tablets:results of a 6-week,randomized,placebo-controlled study[J]. Biol Psyehiatry,2007,62(12):1363-1370.
[8] Canuso CM,Bossie CA,Turkoz I,et al.Paliperidone extended-release for schizophrenia:effects on symptoms and functioning in acutely ill patients with negative symptoms[J].Schizophrenia Research,2009,l13(1):56-64.
[9] 周平, 陈云春, 王化宁,等.帕利哌酮缓释片与利培酮片治疗精神分裂症对照研究[J]. 临床精神医学杂志,2010,20(6 ):368-370.
[10] Dremencov E, Mansani ME I, Blier P, et al.Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat seroton in and norep inephrinen eurons[J]. Psychopharmacology, 2007, 194(1): 63-72.
[11] Herbert YM,William VB,Isaax FN,et al.Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia:pooled data from three 6-week,placebo-controlled studies[J].J Clin Psychiatry,2008,69(5):817-829.
[12] 王旸,曹昱,张艳.帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究[J].精神医学杂志,2009,22(6):415-419.
[13] Davidson M,Emsley R,Kramer M,et al.Efficacy,safety and early response of paliperidone extended-release tablets ( paliperidone ER):Results of a 6-week, randomized,placebo-controlled study[J].J Schizophrenia Research,2007,93(1/2/3):117-130.

[1]	李娜, 韩鸿璨, 王骏. 以药动学方法评价的抗精神分裂症药物人体生物等效性研究的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(12): 1419-1425.
[2]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[3]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[4]	胡德凤，王轶虎，龙小宇，王广水. 甘麦大枣汤加减方联合认知行为干预对精神分裂症超高危人群的干预作用及对认知功能、生活质量及血清5-HT、MT、TSH水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 546-553.
[5]	樊垚，薛永，汪昕，陈雪菲，张旭，姚应水，沈冲. 载脂蛋白E基因多态性与利培酮所致体质量降低的关联研究[J]. 中国临床药理学与治疗学, 2019, 24(3): 288-295.
[6]	曹婷，李娜娜，蔡骅琳. 神经甾体在精神分裂症发病与治疗中作用的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(6): 709-714.
[7]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[8]	周勇，陈雪芳，黄汉津. 氨磺必利治疗精神分裂症疗效以及安全性研究[J]. 中国临床药理学与治疗学, 2017, 22(10): 1152-1157.
[9]	陶怀, 魏钦令, 杨佳锦, 刘勇, 唐姝娟. 不同剂量帕潘立酮治疗对精神分裂症发育模型大鼠行为学的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 1001-1006.
[10]	杨艳，夏泳，朱长江，陈艳波. 阿立哌唑对氨磺必利所致高泌乳素血症的影响研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 693-696.
[11]	杭荣华, 李业平, 吴明飞, 李瑞. 门诊精神分裂症患者药物治疗的依从性与不良反应、社会支持的关系[J]. 中国临床药理学与治疗学, 2014, 19(8): 912-915.
[12]	倪平, 吕海龙, 国效峰, 张丽丽, 许林勇. 利培酮与奥氮平对精神分裂症急性期的疗效及临床影响因素的比较[J]. 中国临床药理学与治疗学, 2014, 19(2): 182-185.
[13]	唐亚梅, 张向晖, 刘勇. 地佐环平诱导的精神分裂症发育模型大鼠脑组织去甲肾上腺素、5-羟色胺及代谢产物的浓度变化[J]. 中国临床药理学与治疗学, 2012, 17(7): 721-726.
[14]	杭荣华, 程万良, 王瑞权, 吴明飞. 奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较[J]. 中国临床药理学与治疗学, 2012, 17(7): 812-815.
[15]	刘林晶, 修梅红, 张向阳, 陈大春. 利培酮对首发精神分裂症S100B蛋白含量影响与疗效关系[J]. 中国临床药理学与治疗学, 2012, 17(3): 313-317.